LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

BioMarin Pharmaceutical Inc

Закрыт

СекторЗдравоохранение

54.39 0.97

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

53.56

Макс.

55.16

Ключевые показатели

By Trading Economics

Доход

241M

426M

Продажи

80M

825M

P/E

Средняя по отрасли

15.958

35.293

Прибыль на акцию

1.44

Рентабельность продаж

51.637

Сотрудники

3,040

EBITDA

95M

319M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+82.78% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

28 окт. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.2B

10B

Предыдущая цена открытия

53.42

Предыдущая цена закрытия

54.39

Новостные настроения

By Acuity

15%

85%

19 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

17 сент. 2025 г., 23:01 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 сент. 2025 г., 22:48 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 сент. 2025 г., 21:59 UTC

Отчет

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 сент. 2025 г., 23:44 UTC

Обсуждения рынка

Nikkei May Rise as Yen Weakens -- Market Talk

17 сент. 2025 г., 23:39 UTC

Обсуждения рынка

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 сент. 2025 г., 22:19 UTC

Приобретения, слияния, поглощения

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 сент. 2025 г., 22:18 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 сент. 2025 г., 21:00 UTC

Отчет

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

17 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

17 сент. 2025 г., 19:59 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 19:59 UTC

Обсуждения рынка

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 сент. 2025 г., 19:07 UTC

Обсуждения рынка

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 сент. 2025 г., 18:43 UTC

Обсуждения рынка

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 сент. 2025 г., 18:38 UTC

Обсуждения рынка

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 сент. 2025 г., 18:20 UTC

Обсуждения рынка

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 сент. 2025 г., 18:18 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 18:18 UTC

Обсуждения рынка

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 сент. 2025 г., 18:14 UTC

Обсуждения рынка

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 сент. 2025 г., 17:59 UTC

Обсуждения рынка

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 сент. 2025 г., 17:15 UTC

Приобретения, слияния, поглощения

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 сент. 2025 г., 17:06 UTC

Приобретения, слияния, поглощения

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 сент. 2025 г., 16:51 UTC

Отчет

Correct: Exor 1H Net Loss -EUR624M

17 сент. 2025 г., 16:34 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 16:34 UTC

Обсуждения рынка

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 сент. 2025 г., 16:25 UTC

Отчет

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 сент. 2025 г., 16:23 UTC

Отчет

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Сравнение c конкурентами

Изменение цены

BioMarin Pharmaceutical Inc Прогноз

Целевая цена

By TipRanks

82.78% рост

Прогноз на 12 месяцев

Средняя 98.59 USD  82.78%

Максимум 122 USD

Минимум 60 USD

Основано на мнении 24 аналитиков Wall Street, спрогнозировавших целевые цены для BioMarin Pharmaceutical Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

24 ratings

20

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

59.405 / 62.19Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Very Strong Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

19 / 371Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat